Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160642 | 0.87 | PARP1 (0.58) | PARP1CDK4CCND1PRKCBPRKCA | |
| SCHEMBL12256417 | 0.72 | PARP1 (1.00) | PARP1 | |
| SCHEMBL29435084 | 0.72 | PARP1 (1.00) | PARP1 | |
| SCHEMBL21160075 | 0.66 | PARP1 (0.38) | PARP1CDK4CCND1 | |
| SCHEMBL21155625 | 0.63 | PARP1 (0.70) | PARP1 | |
| SCHEMBL21160645 | 0.61 | PARP1 (0.74) | PARP1 | |
| SCHEMBL19693056 | 0.55 | PRKCB (0.45) | PRKCBPRKCA | |
| SCHEMBL15968615 | 0.55 | PARP1 (0.57) | PARP1CDK4CCND1PRKCBPRKCA | |
| SCHEMBL14980870 | 0.54 | PARP1 (1.00) | PARP1CDK4CCND1PRKCBPRKCA | |
| SCHEMBL24119475 | 0.54 | CA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | PARP1 1881/4885CDK4 1178/4885CCND1 4407/4885 |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, VHL | PARP1 1881/4885CDK4 1178/4885CCND1 4407/4885 |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | PARP1 1881/4885CDK4 1178/4885CCND1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.